Life Spine has earned U.S. Food and Drug Administration (FDA) clearance for its GRUVE+ cervical plating system.

GRUVE+, according to the company, features an advanced design and seamlessly integrates with its cervical spacers. It also addresses the various needs of surgeons and patients to boost surgical efficiency and outcomes.

A streamlined plate-cage attachment offers flexible connection in-situ or before insertion. Specialized sub-flush design accommodates osteophytes for improved comfort, as well. GRUVE+ has two-hole and four-hole configurations to accommodate anatomical preferences.

The system’s self-drilling/self-tapping screws have high angulation trajectory for varied anatomies. Its CAM locking mechanism provides visual, tactile, and audible feedback to secure screws and prevent back-out. Also, it integrates with the company’s PLATEAU-C/PLATEAU-C Ti and Pro-Link/Pro-Link Ti platforms.

GRUVE+’s large graft window maximizes material containment for robust fusion, Life Spine said.

“This FDA 510(k) clearance marks a significant milestone,” said Mariusz Knap, Life Spine’s senior vice president of marketing. “GRUVE + offers seamless plate/cage attachment and delivers the precision, safety, and adaptability surgeons demand while improving outcomes for patients.”

Last month, the company received FDA clearance for its ProLift Pivot expandable spacer system. The device features in-situ expansion of up to 5 mm to optimize alignment, with the ability to collapse and expand for precision repositioning.